Experimental Therapeutics Section


Laboratory of Experimental Immunology (LEI), National Cancer Institute, National Institutes of Health.

Robert H. Wiltrout, Ph.D., Section Head

WILTROUTR@MAIL.NCIFCRF.GOV

Kristin L. Komschlies, Ph.D.,Principal Investigator

KOMSCHLIESK@NCIFCRF.GOV

Section Goals:

(1) Develops appropriate models in experimental animals that parallel the growth and dissemination observed clinically in human tumors; (2) utilizes the animal models to study the treatment of primary tumors and/or metastases by biological response modifiers (BRMs), monoclonal antibodies, or adoptively transferred cytolytic lymphocytes, either alone or in conjunction with chemotherapeutic drugs; (3) investigates the immunological and cell biological mechanisms by which BRMs mediate antitumor/antimetastatic effects in various organs or anatomical compartments;and (4) studies the regulation and mobilization of committed hematopoietic progenitor and pluripotent ste m cells by cytokines; and applies these findings to dose escalation of chemotherapeutic drugs.

Experimental Therapeutics Section References

Laboratory of Experimental Immunology Home Page

National Cancer Institute Home Page

This document was prepared by John Ortaldo, Ph.D..

Updated: July 1, 1996